MARKET

ANAB

ANAB

AnaptysBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.96
+0.32
+1.30%
Opening 12:38 11/25 EST
OPEN
24.71
PREV CLOSE
24.64
HIGH
25.19
LOW
24.39
VOLUME
70.67K
TURNOVER
--
52 WEEK HIGH
31.29
52 WEEK LOW
12.06
MARKET CAP
682.60M
P/E (TTM)
-9.2144
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
On Nov. 11, AnaptysBio Terminated Sublease With Trex Enterprises Corp. With Respect To Facilities In San Diego, CA Building
-Reuters
Reuters · 11/17 21:12
AnaptysBio EPS misses by $0.15
AnaptysBio (ANAB): Q3 GAAP EPS of -$0.87 misses by $0.15.Cash, cash equivalents and investments of $374.5M.Press Release
Seekingalpha · 11/04 21:52
AnaptysBio Q3 EPS $(1.96) Down From $(1.15) YoY
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.96) per share. This is a 70.43 percent decrease over losses of $(1.15) per share from the same period last year.
Benzinga · 11/04 21:01
GlaxoSmithKline, AnaptysBio amend immuno-oncology pact
AnaptysBio (ANAB) and GlaxoSmithKline (GSK) have amended their immuno-oncology collaboration agreement that now provides AnaptysBio with increased royalties on dostarlimab sales, a royalty on GSK’s Zejula and a one-time cash
Seekingalpha · 10/26 12:54
AnaptysBio, GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in
Benzinga · 10/26 12:05
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Allscripts Healthcare Solutions Shares Jump
Toward the end of trading Wednesday, the Dow traded down 0.45% to 28550.31 while the NASDAQ fell 0.75% to 11775.45. The S&P also fell, dropping 0.56% to 3,492.39.
Benzinga · 10/14 18:33
Allscripts Healthcare, Concho Resources: 5 Top Stock Gainers for Wednesday
Allscripts, AnaptysBio, Concho Resources, Voxx International and Nio are five top stock gainers for Wednesday.
TheStreet.com · 10/14 18:16
Truist raises AnaptysBio's price target by 25%
AnaptysBio ([[ANAB]] +12.6%) had its price target lifted by Truist from $16 to $20, and keeps a Buy rating on the stockThe analyst cites the company's positive imsidolimab data from
Seekingalpha · 10/14 17:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANAB. Analyze the recent business situations of AnaptysBio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANAB stock price target is 28.00 with a high estimate of 42.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 218
Institutional Holdings: 45.27M
% Owned: 165.53%
Shares Outstanding: 27.35M
TypeInstitutionsShares
Increased
31
878.69K
New
35
325.42K
Decreased
51
2.08M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.48%
Pharmaceuticals & Medical Research
+0.19%
Key Executives
Chairman/Independent Director
James Topper
President/Chief Executive Officer/Director
Hamza Suria
Chief Financial Officer
Dennis Mulroy
Chief Operating Officer/General Counsel
Eric Loumeau
Other
Paul Lizzul
Lead Director/Independent Director
Hollings Renton
Independent Director
Dennis Fenton
Independent Director
Laura Hamill
Independent Director
John Schmid
Independent Director
J. Ware
Independent Director
J. Anthony Ware
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AnaptysBio Inc stock information, including NASDAQ:ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.